[{"id":"92df4bc8-e2d0-425b-bf01-0b315be78bf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01251926","created_at":"2021-01-18T05:02:45.026Z","updated_at":"2024-07-02T16:36:53.644Z","phase":"Phase 1","brief_title":"EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors","source_id_and_acronym":"NCT01251926","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HIF1A","pipe":"","alterations":" ","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • firtecan pegol (PEG-SN38)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/15/2010","start_date":" 11/15/2010","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 04/23/2014","study_completion_date":" 04/23/2014","last_update_posted":"2019-11-15"},{"id":"ab662527-c265-4446-8d67-67417cb82de4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01301547","created_at":"2021-01-18T05:17:28.789Z","updated_at":"2024-07-02T16:37:17.273Z","phase":"","brief_title":"Bevacizumab and Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin in Treating Patients With Refractory Solid Tumors","source_id_and_acronym":"NCT01301547","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • irinotecan • firtecan pegol (PEG-SN38)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-06"}]